IDEXX Laboratories Schedules Two Institutional Investor Events
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming institutional investor events:
Thursday, January 4, 2024, 1:30 pm EST - Jay Mazelsky, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference in New York, New York.
Monday, January 15, 2024, 1:00 pm EST - Jay Mazelsky and members of the IDEXX management team will host an Investor and Analyst Session at VMX in Orlando, Florida highlighting IDEXX's new point of care analyzer. On-site participation is limited and advance registration for the in-person event is required; institutional investors and analysts interested in attending should contact [email protected].
Individuals can access live audio webcasts of the fireside chat and VMX presentation through links on the IDEXX website, www.idexx.com/investors. Archived editions of the events will be available via the same links.
About IDEXX Laboratories
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions?to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs nearly 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit www.idexx.com.
The global gastroesophageal reflux disease (GERD) market size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 3.2% during the forecast period. Rising geriatric...
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.
Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...